Sector News

DSM Managing Board re-appointments

March 19, 2015
Life sciences
Royal DSM, the global Life Sciences and Materials Sciences company, today announces the proposed re-appointment of Stephan B. Tanda as member of the DSM Managing Board at the upcoming Annual General Meeting of Shareholders (AGM) on 30 April 2015. DSM also announces the departure of DSM Managing Board member Stefan Doboczky per 1 June 2015.
 
The transformation of the DSM pharmaceutical activities was completed in 2014, and DSM now holds participations in two joint ventures. As a result, it has been agreed between DSM and Stefan Doboczky that his term as a Managing Board member will not be renewed at the upcoming AGM. Stefan will leave DSM per 1 June  and has accepted employment outside of DSM.
 
Stefan Doboczky has worked in DSM’s Pharma businesses for 17 years and has, as a Managing Board member, successfully led the design and execution of the Pharma strategy, resulting in the creation of DSM Sinochem Pharmaceuticals (DSP, Antibiotics JV with Sinochem) and DPx (Pharma JV with JLL/Patheon).
 
The responsibilities of Stefan Doboczky will be redistributed among the current Managing Board members.
 
Feike Sijbesma, CEO and Chairman of the DSM Managing Board, commented: “During the years that Stefan worked for DSM in Pharma and as Regional President in Asia, he spearheaded many strategic growth initiatives that helped transform our business. DSM is very grateful for the contribution he has made over many years and, also on behalf of my colleagues, I wish him every success in the next step in his career.”
 
Source: DSM

comments closed

Related News

March 2, 2024

Seeking blockbuster status, UCB eyes 4 new indications for psoriasis med Bimzelx in 2024

Life sciences

After 14 regulatory approvals on three continents last year, UCB is positioned to grow for “a decade-plus,” CEO Jean-Christophe Tellier said in the company’s full-year earnings press release. Meanwhile, eight regulatory reviews are ongoing.

March 2, 2024

Argenx goes again, ramping up unbranded campaign ahead of hoped-for label expansion

Life sciences

Vyvgart Hytrulo, the subcutaneous version of argenx’s FcRn blocker, is already approved in generalized myasthenia gravis (gMG). Supported by data published last year, the biotech has filed for approval in a second setting, chronic inflammatory demyelinating polyneuropathy (CIDP), and is now counting down the weeks until the FDA rules on its submission.

March 2, 2024

EuroAPI appoints new CEO and lays out restructuring plan as manufacturer’s losses mount

Life sciences

Overseeing the four-year plan, dubbed FOCUS-27, will be new chief executive officer Ludwig de Mot—an industry veteran with a track record at “companies undergoing transformation,” EuroAPI said in an earnings release Wednesday. De Mot, who will take up the reins on Friday, joined the company in January as EuroAPI’s chief transformation officer.

How can we help you?

We're easy to reach